Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....
In the realm of cardiac health, an exciting new study has cast light on the intricate details of our hearts, revealing significant differences between the left and right ventricles' fibroblasts. This research, conducted by a team of dedicated scientists from the...
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...
An innovative cardiovascular start-up, HDAX Therapeutics, is the latest company to win $250,000 in funding following another year of the Ted Rogers Centre for Heart Research’s Entrepreneurship for Cardiovascular Health Opportunities (ECHO) program. The ECHO program...
Several members of the Ted Rogers Centre for Heart Research (TRCHR) participated in Vascular 2023, a five-day conference held in Montreal from October 25-29. The conference is a hallmark event organized by several Canadian specialist and research organizations,...
Researchers at the Ted Rogers Centre for Heart Research have developed an innovative approach to better understanding the complex signaling mechanisms underlying heart failure. A recent publication in the Proceedings of the National Academy of Sciences (PNAS) offers...
Through better treatments, in recent decades we are witnessing an exponential rise in the number of adults who live with congenital heart disease (CHD) acquired at birth. That includes those who want to start families.
A CHD patient who is also an expecting mother is a relatively new field of study. Her heart’s output rises 50% as hemodynamics change and the cardiovascular system responds to mother and fetus. We must ensure both are safe and healthy during the months of pregnancy.
“Right now, when a mom with congenital heart disease is pregnant, physicians don’t know what will happen,” said Dr. Davide Marini, a Ted Rogers Centre-funded researcher at SickKids. “They can’t be certain they are making the right decision to wait full term or deliver early. Because we don’t have the information to base these decisions on yet.”
In France an
d Italy, Dr. Marini was a physician training in pediatric cardiology when his chief suggested he consider fetal cardiac MRI – a burgeoning field. It was then he came upon the work of Dr. Mike Seed, fetal cardiologist at SickKids.
“It was fascinating,” Dr. Marini said. “At once, he was studying not only the fetal heart and circulation, but its relationship with the brain, fetal growth – and the same with the mother.”
Now on sabbatical with Dr. Seed, Dr. Marini is helping craft a new technological approach to fetal cardiac imaging. This major advance in image quality makes it possible to capture stunning expressions of the heart of the fetus. Improving image quality and the software capable of capturing it is in part thanks to technology developed by Christopher Macgowan and his team at SickKids.
“Using MRI to measure fetal circulation may be very helpful to understand the effectiveness of interventional procedures on the fetus, and whether certain drugs will be effective,” said Dr. Marini.
Dr. Marini said they are studying three components of CHD-impacted pregnancy:
One key aspect is studying the amount of oxygen delivered to the fetus and placenta. Using imaging sequences, they can calculate the blood flow’s oxygen content, ensuring the baby’s neurological development is healthy.
Such studies could have a major impact on how to make difficult clinical decisions. If you discover the mother or fetus is suffering too much, it would help with the decision to induce delivery early. Ultimately they hope to pinpoint the criteria with which physicians could make these determinations.
As of this story, the team has scanned 13 pregnant women and 13 others who have congenital heart diseases. They will publish data upon reaching 20 women in each category who consent to be part of this ground-breaking research. Dr. Rachel Wald, an adult congenital cardiologist at Peter Munk Cardiac Centre, is collaborating and providing care for the expecting mothers.
Preliminary data shows that uterine arties in pregnant women possess a significant blood flow, more than 1 litre per minute, meaning a luxurious amount of oxygen. They’ve found the body extracts just 16% for the fetus and placenta. This fact means the mother’s cardiovascular system builds a wide safety net around any risk for fetal hypoxia.
Dr. Marini said that even in pregnant women with severe valvular regurgitation or ventricular dysfunction, this cardiac output is well preserved. Only those expecting mothers with single ventricle physiology risk delivering inadequate blood flow to the fetus.
Up next: the team is beginning to look at the mother’s heart function a half-year after delivery, to gauge post-partum blood flow, and any resulting impact to the heart.
***
Images and video provided by Davide Marini. He received a 2016 Education Fund grant from the Ted Rogers Centre.
